End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
67.46
CNY
|
-5.12%
|
|
-2.03%
|
+3.63%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,293
|
7,389
|
7,091
|
7,154
|
-
|
-
|
Enterprise Value (EV)
1 |
9,293
|
7,389
|
7,091
|
7,154
|
7,154
|
7,154
|
P/E ratio
|
62.7
x
|
38.2
x
|
25.9
x
|
19.1
x
|
14
x
|
10.8
x
|
Yield
|
-
|
1.17%
|
0.46%
|
1.72%
|
1.84%
|
3.02%
|
Capitalization / Revenue
|
-
|
12.2
x
|
6.97
x
|
5.25
x
|
4.08
x
|
3.08
x
|
EV / Revenue
|
-
|
12.2
x
|
6.97
x
|
5.25
x
|
4.08
x
|
3.08
x
|
EV / EBITDA
|
-
|
32.2
x
|
18.2
x
|
13.8
x
|
10.9
x
|
8.21
x
|
EV / FCF
|
-
|
-
|
-11.9
x
|
-53
x
|
-26.6
x
|
-59.6
x
|
FCF Yield
|
-
|
-
|
-8.43%
|
-1.89%
|
-3.76%
|
-1.68%
|
Price to Book
|
-
|
2.98
x
|
2.64
x
|
2.39
x
|
2.13
x
|
1.86
x
|
Nbr of stocks (in thousands)
|
108,167
|
108,167
|
108,920
|
108,143
|
-
|
-
|
Reference price
2 |
85.91
|
68.31
|
65.10
|
66.15
|
66.15
|
66.15
|
Announcement Date
|
3/14/22
|
3/12/23
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
607.4
|
1,017
|
1,363
|
1,754
|
2,319
|
EBITDA
1 |
-
|
229.2
|
388.8
|
519
|
656.3
|
871.5
|
EBIT
1 |
-
|
188.6
|
297
|
402.5
|
545.8
|
711.7
|
Operating Margin
|
-
|
31.06%
|
29.19%
|
29.54%
|
31.11%
|
30.68%
|
Earnings before Tax (EBT)
1 |
-
|
190.9
|
295.7
|
403
|
546.2
|
712
|
Net income
1 |
111
|
194.2
|
272
|
377.7
|
513.3
|
666.5
|
Net margin
|
-
|
31.97%
|
26.73%
|
27.72%
|
29.26%
|
28.74%
|
EPS
2 |
1.370
|
1.790
|
2.510
|
3.467
|
4.720
|
6.117
|
Free Cash Flow
1 |
-
|
-
|
-597.9
|
-135
|
-269
|
-120
|
FCF margin
|
-
|
-
|
-58.77%
|
-9.91%
|
-15.34%
|
-5.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.8000
|
0.3000
|
1.135
|
1.217
|
2.000
|
Announcement Date
|
3/14/22
|
3/12/23
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-598
|
-135
|
-269
|
-120
|
ROE (net income / shareholders' equity)
|
-
|
8.15%
|
10.6%
|
12.7%
|
15.3%
|
17.1%
|
ROA (Net income/ Total Assets)
|
-
|
6.63%
|
-
|
8.62%
|
11%
|
11.6%
|
Assets
1 |
-
|
2,927
|
-
|
4,382
|
4,654
|
5,751
|
Book Value Per Share
2 |
-
|
23.00
|
24.60
|
27.60
|
31.00
|
35.60
|
Cash Flow per Share
2 |
-
|
2.400
|
0.8300
|
4.240
|
5.520
|
6.840
|
Capex
1 |
-
|
591
|
688
|
606
|
443
|
581
|
Capex / Sales
|
-
|
97.3%
|
67.66%
|
44.47%
|
25.24%
|
25.05%
|
Announcement Date
|
3/14/22
|
3/12/23
|
4/22/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +3.63% | 1.01B | | +23.08% | 44.96B | | +1.12% | 42.65B | | +45.83% | 41.85B | | -5.31% | 29.04B | | +11.09% | 26.08B | | -21.12% | 19.03B | | +6.22% | 12.75B | | +28.97% | 12.06B | | -3.78% | 11.75B |
Other Biotechnology & Medical Research
|